Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study

Osteoporosis International

Volumn 27, Issue 1, 2016, Pages 387-396

  Brozek, W ^a   Reichardt, B ^b   Zwerina, J ^a   Dimai, H P ^c   Klaushofer, K ^a   Zwettler, E ^a  

^a AUVA Soziale Unfallversicherung   (Austria)

^b Burgenland Regional Health Insurance Fund   (Austria)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Bisphosphonates; Epidemiology; Hip fracture; Mortality; Osteoporosis; Refracture

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; DENOSUMAB; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; PRESCRIPTION DRUG; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ADULT; AGE; AGED; ANTIRESORPTIVE THERAPY; ARTICLE; AUSTRIA; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG THERAPY; FEMALE; FRACTURE; FRAGILITY FRACTURE; HIGH RISK PATIENT; HIP FRACTURE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OSTEOPOROSIS; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; REFRACTURE; RETROSPECTIVE STUDY; SEX DIFFERENCE; SURVIVAL RATE; TREATMENT OUTCOME; AGE DISTRIBUTION; EPIDEMIOLOGY; HIP FRACTURES; MIDDLE AGED; OSTEOPOROTIC FRACTURES; PROCEDURES; RECURRENT DISEASE; RISK ASSESSMENT; SEX RATIO; VERY ELDERLY;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; AUSTRIA; BONE DENSITY CONSERVATION AGENTS; FEMALE; HIP FRACTURES; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEX DISTRIBUTION;

EID: 84955202813     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-015-3415-4     Document Type: Article

References (45)

1. Dhanwal DK, Dennison EM, Harvey NC, Cooper C (2011) Epidemiology of hip fracture: worldwide geographic variation. Indian J Orthop 45:15–22
2. Haleem S, Lutchman L, Mayahi R, Grice JE, Parker MJ (2008) Mortality following hip fracture: trends and geographical variations over the last 40 years. Injury 39:1157–1163
3. Armstrong AL, Wallace WA (1994) The epidemiology of hip fractures and methods of prevention. Acta Orthop Belg 60(S1):85–101
4. McClung MR (2003) Pathogenesis of osteoporotic hip fractures. Clin Cornerstone 5(S2):S22–S29
5. Bischoff-Ferrari H (2011) The role of falls in fracture prediction. Curr Osteoporos Rep 9:116–121
6. Boonen S, Lips P, Bouillon R, Bischoff-Ferrari HA, Vanderschueren D, Haentjens P (2007) Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab 92:1415–1423
7. Abrahamsen B, Masud T, Avenell A, Anderson F, Meyer HE, Cooper C et al (2010) Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe. BMJ 340:b5463
8. Rizzoli R (2011) Bisphosphonates for post-menopausal osteoporosis: are they all the same? QJM 104:281–300
9. Reginster J-Y (2011) Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. Drugs 71:65–78
10. Alves SM, Economou T, Oliveira C, Ribeiro AI, Neves N, Goméz-Barrena E et al (2013) Osteoporotic hip fractures: bisphosphonates sales and observed turning point in trend. A population-based retrospective study. Bone 53:430–436
11. Fisher AA, O’Brien ED, Davis MW (2009) Trends in hip fracture epidemiology in Australia: possible impact of bisphosphonates and hormone replacement therapy. Bone 45:246–253
12. Brauer C, Coca-Perraillon M, Cutler DM, Rosen AB (2009) Incidence and mortality of hip fractures in the United States. JAMA 302:1573–1579
13. Dimai HP, Svedbom A, Fahrleitner-Pammer A, Pieber T, Resch H, Zwettler E et al (2011) Epidemiology of hip fractures in Austria: evidence for a change in the secular trend. Osteoporos Int 22:685–692
14. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765
15. Eriksen EF, Keaveny TM, Gallagher ER, Krege JH (2014) Literature review: the effects of teriparatide therapy at the hip in patients with osteoporosis. Bone 67:246–256
16. Center JR, Bliuc D, Nguyen ND, Nguyen TV, Eisman JA (2014) Osteoporosis medication and reduced mortality risk in elderly women and men. J Clin Endocrinol Metab 96:1006–1014
17. Sambrook PN, Cameron ID, Chen JS, March LM, Simpson JM, Cumming RG et al (2011) Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study. Osteoporos Int 22:2551–2556
18. Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809
19. Cameron ID, Chen JS, March LM, Simpson JM, Cumming RG, Seibel MJ et al (2010) Hip fracture causes excess mortality owing to cardiovascular and infectious disease in institutionalized older people: a prospective 5-year study. J Bone Miner Res 25:866–872
20. Beaupre LA, Morrish DW, Hanley DA, Maksymowych WP, Bell NR, Juby AG et al (2011) Oral bisphosphonates are associated with reduced mortality after hip fracture. Osteoporos Int 22:983–991
21. Bondo L, Eiken P, Abrahamsen B (2013) Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients—a nationwide register-based open cohort study. Osteoporos Int 24:245–252
22. Bolland MJ, Grey AB, Gamble GD, Reid IR (2010) Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab 95:1174–1181
23. Nieves JW, Cosman F (2010) Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates. Curr Osteoporos Rep 8:34–39
24. Abrahamsen B, Eiken P, Eastell R (2009) Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 24:1095–1102
25. Lee Y-K, Ha Y-C, Park C, Yoo JJ, Shin CS, Koo K-H (2013) Bisphosphonate use and increased incidence of subtrochanteric fracture in South Korea: results from the National Claim Registry. Osteoporos Int 24:707–711
26. Lee Y-K, Ha Y-C, Choi HJ, Jang S, Park C, Lim Y-T et al (2013) Bisphosphonate use and subsequent hip fracture in South Korea. Osteoporos Int 24:2887–2892
27. Shen S-H, Huang K-C, Tsai Y-H, Yang T-Y, Lee MS, Ueng SWN et al (2014) Risk analysis for second hip fracture in patients after hip fracture surgery: a nationwide population-based study. J Am Med Dir Assoc 15:725–731
28. Brozek W, Reichardt B, Kimberger O, Zwerina J, Dimai HP, Kritsch D et al (2014) Mortality after hip fracture in Austria 2008–2011. Calcif Tissue Int 95:257–266
29. Willson T, Nelson SD, Newbold J, Nelson RE, LaFleur J (2015) The clinical epidemiology of male osteoporosis: a review of the recent literature. Clin Epidemiol 7:65–76
30. Ryg J, Rejnmark L, Overgaard S, Brixen K, Vestergaard P (2009) Hip fracture patients at risk of second hip fracture: a nationwide population-based cohort study of 169,145 cases during 1977–2001. J Bone Miner Res 24:1299–1307
31. Lawrence TM, Wenn R, Boulton CT, Moran CG (2010) Age-specific incidence of first and second fractures of the hip. J Bone Joint Surg (Br) 92:258–261
32. Nymark T, Lauritsen JM, Ovesen O, Röck ND, Jeune B (2006) Short time-frame from first to second hip fracture in the Funen County Hip Fracture Study. Osteoporos Int 17:1353–1357
33. Lönnroos E, Kautiainen H, Karppi P, Hartikainen S, Kiviranta I, Sulkava R (2007) Incidence of second hip fractures. A population-based study. Osteoporos Int 18:1279–1285
34. Ishtiaq S, Fogelman I, Hampson G (2015) Treatment of post-menopausal osteoporosis: beyond bisphosphonates. J Endocrinol Investig 38:13–29
35. Colón-Emeric CS, Mesenbrink P, Lyles KW, Pieper CF, Boonen S, Delmas P et al (2010) Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res 25:91–97
36. Le Goff B, Berthelot J-M, Maugars Y, Romas E (2010) Alternative use of bisphosphonate therapy for rheumatic disease. Curr Pharm Des 16:3045–3052
37. Criscitiello C, Viale G, Gelao L, Esposito A, De Laurentiis M, De Placido S et al (2015) Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment. Cancer Treat Rev 41:61–68
38. Santos LL, Cavalcanti TB, Bandeira FA (2012) Vascular effects of bisphosphonates—a systematic review. Clin Med Insights Endocrinol Diabetes 5:47–54
39. Kim DH, Rogers JR, Fulchino LA, Kim CA, Solomon DH, Kim SC (2015) Bisphosphonates and risk of cardiovascular events: a meta-analysis. PLoS One 10:e0122646
40. Thaler R, Spitzer S, Karlic H, Berger C, Klaushofer K, Varga F (2013) Ibandronate increases the expression of the pro-apoptotic gene FAS by epigenetic mechanisms in tumor cells. Biochem Pharmacol 85:173–185
41. Coleman R, Gnant M, Morgan G, Clezardin P (2012) Effects of bone-targeted agents on cancer progression and mortality. J Natl Cancer Inst 104:1059–1067
42. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822
43. Misof BM, Patsch JM, Roschger P, Muschitz C, Gamsjaeger S, Paschalis EP et al (2014) Intravenous treatment with ibandronate normalizes bone matrix mineralization and reduces cortical porosity after two years in male osteoporosis: a paired biopsy study. J Bone Miner Res 29:440–449
44. Petri H, Urquhart J (1991) Channeling bias in the interpretation of drug effects. Stat Med 10:577–581
45. Shrank WH, Patrick AR, Brookhart MA (2011) Healthy user and related biases in observational studies of preventive interventions: a primer for physicians. J Gen Intern Med 26:546–550